Preclinical evaluation of 131I-Bevacizumab - A prospective agent for radioimmunotherapy in VEGF expressing cancers.

Abstract

This study focuses on preparation and evaluation of 131I-bevacizumab by Iodogen method for targeting VEGF over-expressing cancers for therapy. 131I-Bevacizumab exhibited radiochemical purity of 98.0±0.7%. In vitro stability of 131I-Bevacizumab was retained at >85% in both saline and serum at 37°C upto 5 days post iodination. In vitro cell studies showed good immunoreactivity and uptake by VEGF expressing tumor cells. Uptake and retention of 131I-Bevacizumab in tumor with reduction in uptake in presence of cold Bevacizumab confirmed its specificity to VEGF.

• Authors: Mythili Kameswaran, Haladhar Dev Sarma, Ashutosh Dash
• Journal: Applied radiation and isotopes : including data, instrumentation and methods for use in agriculture, industry and medicine (Appl Radiat Isot) Vol. 123 Pg. 109-113 (May 2017) ISSN: 1872-9800 [Electronic] England
• PMID: 28260607 (Publication Type: Evaluation Study, Journal Article)
• Copyright: Copyright © 2017 Elsevier Ltd. All rights reserved.

Chemical References

• Antineoplastic Agents, Immunological
• Iodine Radioisotopes
• Radiopharmaceuticals
• VEGFA protein, human
• Vascular Endothelial Growth Factor A
• Bevacizumab

Topics

• Animals
• Antineoplastic Agents, Immunological (pharmacokinetics, therapeutic use)
• Bevacizumab (pharmacokinetics, therapeutic use)
• Cell Line, Tumor
• Human Umbilical Vein Endothelial Cells
• Humans
• Iodine Radioisotopes (pharmacokinetics, therapeutic use)
• Melanoma, Experimental (metabolism, radiotherapy)
• Mice
• Mice, Inbred C57BL
• Radioimmunotherapy (methods)
• Radiopharmaceuticals (pharmacokinetics, therapeutic use)
• Tissue Distribution
• U937 Cells
• Vascular Endothelial Growth Factor A (metabolism)